Cost efficiency of targeted therapy
17 Jul 2012
Cost efficiency of targeted therapy
Society and money - the cancer conundrum
Translating cancer research to personalised treatment: Can it work?
Highlights of the 22nd EACR meeting and tackling glioblastoma
Adjuvant cetuximab disappoints again in mCRC
The WINTHER study
Use of electronic data to raise the standard of cancer care
Drugging the cancer genome: opportunities and challenges
A new direction for development of targeted cancer therapies
Vandetanib increases progression free survival in medullary thyroid carcinoma
WINTHER: The WIN therapeutics clinical trial
Emerging advances in multiple myeloma; expert roundtable at MM CTP 2012